illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. health care
  6. ›
  7. Simcere Pharmaceutical
Company logo

Simcere Pharmaceutical | Sustainability Performance

https://en.simcere.com/

Develops, manufactures, and markets pharmaceutical products.

1995

China

5,001 - 10,000 employees

Pharmaceuticals

$1B - 10B in revenue

$100M - 500M in profitability

Submit or report inaccurate dataDownload Company Insights

Sustainability Ranking & Industry Benchmark

#11042
Overall
#770
in China
#266
in Pharmaceuticals

Sustainability Maturity

​​0123456789​​%

Sustainability Intent

Available in
Scale package

Access
​​0123456789​​%

Industry Rank

261 out of 292

Overview
Governance
TargetsESG scores and Exclusions
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies


Company logo
BioKangtai

China, Health Care, Biotechnology


Company logo
China National Accord Medicines

China, Health Care, Pharmaceuticals


Company logo
Shandong Buchang Pharmaceuticals

China, Health Care, Pharmaceuticals

Market cap

26.8B $, 2026▼33.3% YoY

Revenue

6.6B $, 2024▼0.4% YoY

R&D intensity

21.25% 2024

Controversy level


Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
  • Simcere Pharmaceutical Group Limited, Chinese pharmaceutical major (cancer/CV), has faced sustained Chinese NMPA enforcement scrutiny over alleged inadequate disclosure of multiple oncology product quality at multiple Chinese production facilities, plus the contested 2024 Chinese government NRDL (National Reimbursement Drug List) price negotiations affecting Hong Konglisted institutional shareholders.
Powered by illuminem

Market cap

26.8B $, 2026▼33.3% YoY

Revenue

6.6B $, FY2024▼0.4% YoY

EBITDA

1.1B $, FY2024▼9.1% YoY

Operating margin

17% Industry: -33▼37.1% YoY

P/E ratio

22.9 Industry: 26▼2.6% YoY

Revenue & EBITDA

$6.6BFY2024 revenue

Total Annual
Revenue & EBITDA
($ B)

Annual revenue
EBITDA
3 year change
Powered by illuminem

Margin trends


Margin as % of revenue

Gross margin
Operating margin
Net margin

Powered by illuminem

Free cashflow

628.5M 2024▼231.9% YoY

Capex

762.0M 2024▲28.5% YoY

Debt/equity ratio

0.2 Industry: 0▼NaN% YoY

R&D intensity

21.3%FY2024

R&D as % of revenue

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Return on invested capital

9.0%FY2026

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Analyst revenue estimates & actuals


Analyst consensus vs actuals
($ B)

Actual revenue
Consensus estimates
Estimate only

6.3

▼ 1.0%

2022

6.6

▼ 3.7%

2023

6.6

▼ 2.8%

2024

12.7

2030

Powered by illuminem

Environmental policy coverage

Carbon reduction policy

Not available

Human rights policy

Not available

Recycling policy

Not available

Workplace health & safety policy

Not available

22%
Independent Directors

4 out of 18 incl. management

Powered by illuminem

Overall score

0

Environment

0

Social

0

Governance

0

Exclusion screening

Adult content

Not available

Alcoholic

Not available

Animal testing

Not available

Firearms

Not available

Tobacco

Not available

Gambling

Not available

Nuclear

Not available

Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

Available

Not committed to key sustainability initiatives

Sustainability employees


    Available in
    Scale package

    Access
  • Email

  • Email